Download PDF
Neurochirurgie Scan 2015; 03(03): 203-225
DOI: 10.1055/s-0034-1392464
Fortbildung
Neuroonkologie
© Georg Thieme Verlag KG Stuttgart · New York

Molekulare Marker in der Neuropathologie: heutiger Stand und Perspektiven

Christian Eisenlöffel
,
Wolf C. Müller
Further Information

Publication History

Publication Date:
29 July 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Molekulare Veränderungen können chromosomaler, genetischer oder epigenetischer Natur sein. Die Untersuchungsmethoden müssen dementsprechend ausgewählt, vorgehalten und vom Neuropathologen beherrscht werden. Dieser Artikel fasst die derzeit diagnostisch etablierten molekularen Analysen in der Neuropathologie zusammen. Es sollen in erster Linie molekulare Tests an primären Hirntumoren besprochen werden.

 

  • Literatur

  • 1 Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent groop. Proc Soc Exp Biol Med 1941; 47: 200-202
    CrossrefGoogle Scholar
  • 2 Nakane PK. Simultaneous localization of multiple tissue antigens using the peroxidase-labeled antibody method: a study on pituitary glands of the rat. J Histochem Cytochem 1968; 16: 557-560
    CrossrefGoogle Scholar
  • 3 Nakane PK, Pierce Jr GB. Enzyme-labeled antibodies: preparation and application for the localization of antigens. J Histochem Cytochem 1966; 14: 929-931
    CrossrefGoogle Scholar
  • 4 Avrameas S, Uriel J. [Method of antigen and antibody labelling with enzymes and its immunodiffusion application]. CR hebdom Seances 'Acad Sciences Ser D: Scie Nats 1966; 262: 2543-2545
    Google Scholar
  • 5 Falini B, Taylor CR. New developments in immunoperoxidase techniques and their application. Arc Pathol Lab Med 1983; 107: 105-117
    Google Scholar
  • 6 Louis DN, Ohgaki H, Wiestler OD et al. (eds). WHO classification of tumours of the central nervous system. Lyon: IARC; 2007
    Google Scholar
  • 7 Louis DN, Perry A, Burger P et al. International Society Of Neuropathology – Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014; 24: 429-435
    CrossrefGoogle Scholar
  • 8 Reifenberger J, Reifenberger G, Liu L et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190
    Google Scholar
  • 9 von Deimling A, Fimmers R, Schmidt MC et al. Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp neurol 2000; 59: 544-558
    CrossrefGoogle Scholar
  • 10 Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 2004; 82: 638-655
    CrossrefGoogle Scholar
  • 11 Hartmann C, Mueller W, Lass U et al. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 2005; 64: 10-14
    CrossrefGoogle Scholar
  • 12 von Deimling A, Bender B, Louis DN et al. A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol Appl Neurobiol 1993; 19: 524-529
    CrossrefGoogle Scholar
  • 13 Griffin CA, Burger P, Morsberger L et al. Identification of der (1; 19) (q10; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65: 988-994
    CrossrefGoogle Scholar
  • 14 Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-1479
    CrossrefGoogle Scholar
  • 15 Branle F, Lefranc F, Camby I et al. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 2002; 95: 641-655
    CrossrefGoogle Scholar
  • 16 Jeuken JW, Sijben A, Bleeker FE et al. The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: further elucidation of their genetic “life story”. Brain Pathol 2011; 21: 308-320
    CrossrefGoogle Scholar
  • 17 Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 2002; 12: 67-86
    Google Scholar
  • 18 Lass U, Hartmann C, Capper D et al. Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol 2013; 23: 311-318
    CrossrefGoogle Scholar
  • 19 Sahm F, Koelsche C, Meyer J et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012; 123: 853-860
    CrossrefPubMedGoogle Scholar
  • 20 Sahm F, Lass U, Herold-Mende C et al. Analysis of CIC-associated CpG island methylation in oligoastrocytoma. Neuropathol Appl Neurobiol 2013; 39: 831-836
    CrossrefGoogle Scholar
  • 21 Sahm F, Reuss D, Koelsche C et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014; 128: 551-559
    CrossrefGoogle Scholar
  • 22 van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-2722
    CrossrefPubMedGoogle Scholar
  • 23 Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880
    CrossrefGoogle Scholar
  • 24 Intergroup Radiation Therapy Oncology Group T. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-2714
    CrossrefGoogle Scholar
  • 25 Cairncross G, Wang M, Shaw E et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31: 337-43
    CrossrefPubMedGoogle Scholar
  • 26 van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31: 344-350
    CrossrefPubMedGoogle Scholar
  • 27 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352: 987-996
    CrossrefGoogle Scholar
  • 28 Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New Engl J Med 2000; 343: 1350-1354
    CrossrefGoogle Scholar
  • 29 Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352: 997-1003
    CrossrefGoogle Scholar
  • 30 Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715
    CrossrefPubMedGoogle Scholar
  • 31 Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926
    CrossrefPubMedGoogle Scholar
  • 32 Reifenberger G, Hentschel B, Felsberg J et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012; 131: 1342-1350
    CrossrefGoogle Scholar
  • 33 van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009; 27: 5881-5886
    CrossrefGoogle Scholar
  • 34 Wick W, Meisner C, Hentschel B et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81: 1515-1522
    CrossrefPubMedGoogle Scholar
  • 35 Bady P, Sciuscio D, Diserens AC et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012; 124: 547-560
    CrossrefGoogle Scholar
  • 36 Turcan S, Rohle D, Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (London) 2012; 483: 479-483
    CrossrefGoogle Scholar
  • 37 Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826
    CrossrefGoogle Scholar
  • 38 Dupont JM, Tost J, Jammes H et al. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Analyt Biochem 2004; 333: 119-127
    CrossrefGoogle Scholar
  • 39 Jeuken JW, Cornelissen SJ, Vriezen M et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007; 87: 1055-1065
    CrossrefGoogle Scholar
  • 40 Lorente A, Mueller W, Urdangarin E et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathology 2009; 19: 279-292
    CrossrefGoogle Scholar
  • 41 Lorente A, Mueller W, Urdangarin E et al. Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 2008; 8: 61
    CrossrefGoogle Scholar
  • 42 Cairncross JG, Wang M, Jenkins RB et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014; 32: 783-790
    CrossrefGoogle Scholar
  • 43 Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812
    CrossrefGoogle Scholar
  • 44 Balss J, Meyer J, Mueller W et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602
    CrossrefGoogle Scholar
  • 45 Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474
    CrossrefGoogle Scholar
  • 46 Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (London) 2009; 462: 739-744
    CrossrefGoogle Scholar
  • 47 Xu W, Yang H, Liu Y et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30
    CrossrefGoogle Scholar
  • 48 Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (London) 2012; 483: 474-478
    CrossrefGoogle Scholar
  • 49 Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20: 245-254
    CrossrefGoogle Scholar
  • 50 Capper D, Zentgraf H, Balss J et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118: 599-601
    CrossrefGoogle Scholar
  • 51 Camelo-Piragua S, Jansen M, Ganguly A et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010; 119: 509-511
    CrossrefGoogle Scholar
  • 52 Korshunov A, Meyer J, Capper D et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118: 401-405
    CrossrefGoogle Scholar
  • 53 van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Res 2010; 16: 1597-1604
    CrossrefGoogle Scholar
  • 54 Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750
    CrossrefGoogle Scholar
  • 55 Hartmann C, Hentschel B, Wick W et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010; 120: 707-718
    CrossrefGoogle Scholar
  • 56 Schumacher T, Bunse L, Pusch S et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature (London) 2014; 512: 324-327
    CrossrefGoogle Scholar
  • 57 Pfister S, Janzarik WG, Remke M et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008; 118: 1739-1749
    CrossrefPubMedGoogle Scholar
  • 58 Bar EE, Lin A, Tihan T et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 2008; 67: 878-887
    CrossrefPubMedGoogle Scholar
  • 59 Jones DT, Kocialkowski S, Liu L et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68: 8673-8677
    CrossrefGoogle Scholar
  • 60 Jones DT, Gronych J, Lichter P et al. MAPK pathway activation in pilocytic astrocytoma. Cellular and molecular life sciences: CMLS 2012; 69: 1799-1811
    CrossrefGoogle Scholar
  • 61 Hawkins C, Walker E, Mohamed N et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 2011; 17: 4790-4798
    CrossrefGoogle Scholar
  • 62 Tian Y, Rich BE, Vena N et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. The Journal of molecular diagnostics: JMD 2011; 13: 669-677
    CrossrefGoogle Scholar
  • 63 Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-947
    CrossrefPubMedGoogle Scholar
  • 64 Schindler G, Capper D, Meyer J et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011; 121: 397-405
    CrossrefGoogle Scholar
  • 65 Capper D, Preusser M, Habel A et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011; 122: 11-19
    CrossrefGoogle Scholar
  • 66 Capper D, Berghoff AS, Magerle M et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123: 223-233
    CrossrefGoogle Scholar
  • 67 Chappe C, Padovani L, Scavarda D et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF (V600E) mutation and expression. Brain Pathol 2013; 23: 574-583
    CrossrefGoogle Scholar
  • 68 Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med 2010; 363: 809-819
    CrossrefGoogle Scholar
  • 69 Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol 2013; 114: 237-240
    CrossrefGoogle Scholar
  • 70 Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014; 14: 258
    CrossrefGoogle Scholar
  • 71 Skrypek M, Foreman N, Guillaume D et al. Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediat Blood Cancer 2014; 61: 2099-2100
    CrossrefGoogle Scholar
  • 72 Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (London) 2012; 482: 226-231
    CrossrefGoogle Scholar
  • 73 Wu G, Broniscer A, McEachron TA et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet 2012; 44: 251-253
    CrossrefGoogle Scholar
  • 74 Lewis PW, Elsaesser SJ, Noh KM et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci USA 2010; 107: 14075-14080
    CrossrefGoogle Scholar
  • 75 Buczkowicz P, Hoeman C, Rakopoulos P et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature genetics 2014; 46: 451-456
    CrossrefGoogle Scholar
  • 76 Liu XY, Gerges N, Korshunov A et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124: 615-625
    CrossrefGoogle Scholar
  • 77 Wiestler B, Capper D, Holland-Letz T et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013; 126: 443-451
    CrossrefGoogle Scholar
  • 78 Heaphy CM, de Wilde RF, Jiao Y et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333: 425
    CrossrefGoogle Scholar
  • 79 Reuss DE, Sahm F, Schrimpf D et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015; 129 : 133-146
    CrossrefGoogle Scholar
  • 80 Wiestler B, Capper D, Hovestadt V et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-oncology 2014; 16: 1630-1638
    Google Scholar